CSL Limited (CSJ) - Total Assets
Based on the latest financial reports, CSL Limited (CSJ) holds total assets worth €38.45 Billion EUR as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CSL Limited - Total Assets Trend (2014–2025)
This chart illustrates how CSL Limited's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CSL Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
CSL Limited's total assets of €38.45 Billion consist of 30.1% current assets and 69.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.5% |
| Accounts Receivable | €2.28 Billion | 5.8% |
| Inventory | €6.47 Billion | 16.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €8.12 Billion | 20.6% |
| Goodwill | €8.06 Billion | 20.5% |
Asset Composition Trend (2014–2025)
This chart illustrates how CSL Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CSL Limited's current assets represent 30.1% of total assets in 2025, a decrease from 51.1% in 2014.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, down from 9.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 14.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 20.6% of total assets.
CSL Limited Competitors by Total Assets
Key competitors of CSL Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
ACRO Biomedical Co., Ltd.
TWO:6748
|
Taiwan | NT$607.52 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
CSL Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.86 | 2.22 | 2.19 |
| Quick Ratio | 0.85 | 1.05 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.23 Billion | €5.27 Billion | €3.21 Billion |
CSL Limited - Advanced Valuation Insights
This section examines the relationship between CSL Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.79 |
| Latest Market Cap to Assets Ratio | 1.15 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | €39.40 Billion |
| Market Capitalization | $45.38 Billion USD |
Valuation Analysis
Above Book Valuation: The market values CSL Limited's assets above their book value (1.15x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: CSL Limited's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CSL Limited (2014–2025)
The table below shows the annual total assets of CSL Limited from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €39.40 Billion | +3.63% |
| 2024-06-30 | €38.02 Billion | +4.93% |
| 2023-06-30 | €36.23 Billion | +27.83% |
| 2022-06-30 | €28.35 Billion | +56.12% |
| 2021-06-30 | €18.16 Billion | -19.42% |
| 2020-06-30 | €22.53 Billion | +28.33% |
| 2019-06-30 | €17.56 Billion | +20.45% |
| 2018-06-30 | €14.58 Billion | +22.92% |
| 2017-06-30 | €11.86 Billion | +16.46% |
| 2016-06-30 | €10.18 Billion | +59.10% |
| 2015-06-30 | €6.40 Billion | +1.96% |
| 2014-06-30 | €6.28 Billion | -- |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more